We are excited to announce that Mavacamten was approved for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in the Macau Special Administrative Region. Learn more here: bit.ly/3I3BMAQ

This week we announced our Q1 2023 financial result and shared recent corporate updates including key anticipated milestones. bit.ly/3W5EqMb $LIAN

Today, our Chief Business Officer Brianne Jahn will be speaking on a panel at the 16th Global BioPharma Cross-border Summit 2023, hosted by PwC, MSQ Ventures & BioKatalyst Corporation. The panel will discuss the new opportunities that exist in China cross-border collaborations.

May is Cancer Research Month. In China, cancer is the leading cause of death with 4.5M diagnoses each year. LianBio has an #oncology pipeline dedicated to providing patients with proven therapeutics for #cancers. Learn about our recent strides: bit.ly/3HV7K2p  #NCRM23

The LianBio management team is looking forward to participating in the Jefferies Global Healthcare Conference and Goldman Sachs Annual Global Healthcare Conference in June. Learn more here: bit.ly/3qo9QBT $LIAN

Today we announced positive topline results from our Phase 2a proof-of-concept trial evaluating infigratinib in Chinese patients w/ locally advanced or metastatic #GastricCancer and receipt of Breakthrough Therapy Designation: bit.ly/3MWR0sO$LIAN

Today we announced the completion of enrollment in our pivotal Phase 3 LIBRA #ClinicalTrial of TP-03 in #Chinese patients with Demodex blepharitis. Read more: investors.lianbio.com/news-releases/…

Tune into our fireside chat at the Jefferies Global Healthcare Conference this afternoon at 4:30 for a discussion with management about recent company updates : bit.ly/43hGtzs

Our CEO Yizhe Wang will be participating in a fireside chat at the Goldman Sachs Annual Global Healthcare Conference at 10 am PT/ 1 pm ET. Tune in here: bit.ly/43hGtzs

Our mission is to bring transformative medicines to historically underserved patients in China and throughout Asia. Learn more about the various diseases we are targeting and explore the status of our ongoing clinical trials: bit.ly/3P8sSX3

LianBio would like to wish everyone a healthy and prosperous #DragonBoatFestival.

We are pleased to announce that CAMZYOS® (mavacamten) was approved for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in the Republic of Singapore. Learn more here: bit.ly/43WkqPh

Today we announced a clinical supply agreement with AstraZeneca in China to evaluate BBP-398, an investigational SHP2 inhibitor, in combination with EGFR inhibitor osimertinib in a Phase 1 clinical study for non-small cell lung cancer with EGFR mutations.bit.ly/44KApjz

Next month, we will present efficacy and safety data of mavacamten, our cardiac myosin inhibitor for the treatment of symptomatic obstructive hypertrophic cardiomyopathy, at the European Society of Cardiology Congress 2023. #ESCCongress bit.ly/3DeqLdb

Congratulations to our partner, Tarsus Pharmaceuticals, Inc. , on the U.S. FDA approval of XDEMVY™ for the treatment of #DemodexBlepharitis. Learn more: bit.ly/3q9CgQ0

Today is World #HeadandNeckCancer Awareness Day. At LianBio, we’re advancing new treatment options for cancer, including head and neck squamous cell carcinoma (HNSCC). Learn more about our ongoing clinical trial of NBTXR3 in locally advanced HNSCC: bit.ly/3pOI7dF

Today we recognize #WorldLungCancerDay. #LungCancer is the leading cause of cancer deaths worldwide, with China having one of the highest incidence rates. There is a great unmet need for new treatments for patients. Learn more from World Health Organization (WHO): bit.ly/3Otyj21

Today we announced the first patient was treated in our Ph1 trial of BBP-398 in Non-Small Cell #LungCancer w/ EGFR mutations.  bit.ly/3YhgDtT

Today we announced our Q2 2023 financial results and shared recent corporate updates including key anticipated milestones. bit.ly/3OxS6w1  $LIAN

Data from the Phase 3 EXPLORER-CN trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy were presented today at the European Society of Cardiology 2023 Congress. The data were also published in JAMA Cardiology. #ESCCongress bit.ly/3KW57yD